Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial

Myungsun Lee, Jeongha Mok, Deog Kyeom Kim, Tae Sun Shim, Won-Jung Koh, Doosoo Jeon, Taehoon Lee, Seung Heon Lee, Ju Sang Kim, Jae Seuk Park, Ji Yeon Lee, Song Yee Kim, Jae Ho Lee, Kyung-Wook Jo, Byung Woo Jhun, Young Ae Kang, Joong Hyun Ahn, Chang-Ki Kim, Soyoun Shin, Taeksun Song, Sung Jae Shin, Young Ran Kim, Heejung Ahn, Seokyung Hahn, Ho Jeong Won, Ji Yeon Jang, Sang Nae Cho and Jae-Joon Yim

Abstract

Background: Treatment success rates of multidrug-resistant tuberculosis (MDR-TB) remain unsatisfactory, and long-term use of second-line anti-TB drugs is accompanied by the frequent occurrence of adverse events, low treatment compliance, and high costs. The development of new efficient regimens with shorter treatment durations for MDR-TB will solve these issues and improve treatment outcomes.

(Continued on next page)
Background
Multidrug-resistant tuberculosis (MDR-TB) is a disease caused by Mycobacterium tuberculosis that is resistant to at least isoniazid and rifampicin, the two most important anti-TB drugs. It accounts for 3.5% of newly diagnosed TB patients and 20.5% of retreatment TB patients globally. In 2016, approximately 490,000 people were diagnosed with MDR-TB, approximately 9% of whom had extensively drug-resistant tuberculosis (XDR-TB), which is resistant to isoniazid and rifampicin plus any fluoroquinolone and at least one of three injectable second-line drugs [1, 2]. In South Korea, 852 new patients with MDR-TB were notified in 2016, and this number has been relatively unchanged in recent years [3, 4].

Traditionally, in order to treat MDR-TB, second-line anti-TB drugs must be used for at least 20 months. Additionally, an injectable drug is needed for the first 8 months of treatment [5]. Despite the long duration of treatment, the treatment success rate remains unsatisfactory. According to the latest World Health Organization (WHO) report, the proportion of MDR-TB/rifampicin-resistant TB (RR-TB) patients who successfully completed treatment (i.e., were cured or completed treatment) was as low as 54% [2]. One important reason for disappointing treatment outcomes is non-adherence to treatment; 15% of MDR-TB patients were lost to follow-up before treatment completion [2].

Patients with MDR-TB frequently experience adverse events (AEs) over the treatment course. One report showed that 57.3% of 5346 patients experienced at least one adverse drug event (ADE) including gastrointestinal disorders (32.1%), ototoxicity (14.6%), and psychiatric disorders (13.2%) [6]. Additionally, among 1519 patients who developed ADEs with available data on MDR-TB therapy, 70.4% required a change of MDR-TB treatment [6]. Another report from a Korean TB cohort showed that major ADEs were more frequent in patients being treated with second-line regimens (16%) compared with first-line regimens (2.5%) [7].

Considering all of these issues, a shorter and more convenient regimen for MDR-TB treatment is urgently needed. Fortunately, repurposed anti-TB drugs including linezolid or newly developed drugs including delamanid and bedaquiline are available for patients with MDR-TB [8–11]. Recently, TB research has focused on identifying the optimal combination of existing and new anti-TB drugs to improve treatment outcomes as well as shorten treatment duration [12].

We hypothesize that a new regimen consisting of fully oral medications including delamanid, linezolid, levofloxacin, and pyrazinamide for 9–12 months is non-inferior to the conventional regimen including second-line anti-TB drugs for 20–24 months to treat MDR-TB in terms of treatment outcomes.

Methods/design
Setting
This randomized controlled trial is being conducted at 12 referral hospitals in South Korea. The flow diagram
for the trial is shown in Fig. 1. Patients with pulmonary TB satisfying the inclusion criteria are competitively enrolled by the investigators in the 12 participating hospitals.

**Design**

This is a phase II/III, multicenter, randomized, open-label clinical trial with two arms. Adult pulmonary TB patients with confirmed MDR-TB or RR-TB are eligible. Once eligibility is confirmed and the participant consents to participate, he/she will be randomly assigned to one of the two groups (arm 1 or 2) at a 1:1 ratio.

**Arm 1 (control arm)**

Treatment will be performed according to the 2014 Korean guidelines for the treatment of tuberculosis [13, 14] and the 2014 WHO guidelines [15] (Table 1). Treatment principles include the following: (1) intensive phase regimen comprising four effective second-line anti-TB drugs (including an injectable) and pyrazinamide should be used for a minimum of 8 months duration; (2) at least five active drugs should be used, appropriately selected based on drug susceptibility testing results (e.g., pyrazinamide, an injectable, a fluoroquinolone, prothionamide, and cycloserine); (3) efforts should always be made to use a fluoroquinolone (preferentially levofloxacin or moxifloxacin); (4) prothionamide or cycloserine should be used preferentially, but when it is not possible, p-aminosalicylic acid (PAS) can be used; (5) the recommended length of the intensive phase including injectable is 8 months and the total treatment duration is 20–24 months.

**Arm 2 (investigational arm)**

The regimen consists of fully oral medications including delamanid, linezolid, levofloxacin, and pyrazinamide for 9–12 months (Table 2). Treatment principles include the following: (1) delamanid will be used for the entire treatment period unless it must be stopped for reasons such as AEs; (2) linezolid is started at a dose of 600 mg/day for 2 months and reduced to 300 mg/day in the third month of treatment or earlier when AEs occur; (3) levofloxacin can be substituted with moxifloxacin in case of AE development, and this substitution will not be considered as a drug change since both are fluoroquinolones of similar potency; (4) pyrazinamide can be continued even if pyrazinamide resistance is discovered on the phenotypic drugs susceptibility testing after commencing treatment [15]; (5) total treatment duration is 9 months (40 weeks) when sputum culture conversion occurs within 3 months of treatment or 12 months (52 weeks) when sputum culture conversion occurs between 3 and 6 months of treatment.

The study timeline is shown in Tables 3 and 4. Treatment adherence is evaluated during every visit by a research nurse who keeps track of packages and returned drugs. If scheduled visits are delayed or cancelled, the study team will try to contact participants as soon as possible by telephone.

**Outcomes**

The primary outcome is treatment success rate at 24 months after the initiation of treatment. The secondary outcomes include time to sputum culture conversion to negative on liquid and solid culture media, proportion
of participants with sputum culture conversion at 2 and 6 months of treatment on liquid culture medium, occurrence of AEs grade 3 and above, proportion of participants with treatment success at the end of treatment, proportion of participants reverting to positive sputum culture after the end of treatment, treatment success rates according to pyrazinamide resistance, proportion of deaths, and time to death.

Definitions

**Culture conversion and reversion**
We define sputum culture conversion as two consecutive negative sputum cultures taken at least 4 weeks apart. The date of culture conversion is defined as the date of the initial negative culture. Culture conversion was also defined as a patient who could not expectorate sputum after one negative sputum culture. When two or more positive cultures occur again after negative conversion, it is regarded as reversion.

**Treatment outcomes**
We define treatment outcomes with reference to 2014 WHO Guidelines [15] (Table 5). For the investigational group, 6 months will be considered as the intensive phase. Furthermore, “stopping” of drugs during treatment will not be considered as “drug change.” Both “cured” and “treatment completed” are defined as treatment success. Treatment failure, death, loss to follow-up, transfer out, and relapse are excluded from treatment success.

**Eligibility criteria**
Participants with pulmonary TB satisfying the inclusion criteria are competitively enrolled by investigators in both outpatient and inpatient settings in the 12 participating hospitals. Inclusion criteria are as follows: men and women aged ≥19 and ≤85 years, with confirmed MDR-TB by phenotypic or genotypic drug susceptibility tests or RR-TB by genotypic tests such as Xpert® *Mycobacterium tuberculosis* (MTB)/resistance to rifampin (RIF) assay (Cepheid, Sunnyvale, CA, USA) regardless of being positive for sputum acid-fast bacilli smear, and use of current anti-TB regimen with second-line drugs for ≤14 days at the time of enrollment.

We will exclude patients with any fluoroquinolone-resistant MDR-TB, XDR-TB patients, and pregnant women or women of childbearing age unwilling to use proper contraceptives. Additionally, any of the following factors will lead to exclusion: (1) medical history of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption; (2) history of optic neuropathy or peripheral neuropathy; and (3) the need for ongoing use of prohibited drugs while on study drugs. Additionally, we will exclude patients having any of the following test results: (1) absolute neutrophil count < 2.0 × 10^3/μL, (2) white blood cell count < 3.0 × 10^3/μL, (3) hemoglobin < 7.0 g/dL, (4) serum creatinine > 2.0 mg/dL, (5) aspartate aminotransferase > 100 IU/L, (6) alanine aminotransferase > 100 IU/L, (7) total bilirubin > 2.0 mg/dL, (8) albumin < 2.8 g/dL, and (9) prolonged QT interval (QTc corrected by Fridericia’s formula, QTcF > 500 ms). Finally, patients who have a history of hypersensitivity reaction to the study drugs will be excluded.

**Randomization**
We assign participants to the study arm based on a 1:1 randomization ratio. The randomization sequence was generated by a trial statistician using a block randomization method stratified by the presence/absence of cavitation on baseline chest radiographs and the presence/absence of baseline diabetes mellitus. A web-based randomization system is operated remotely at the Medical Research Collaborating Center (MRCC) in Seoul National University Hospital. Access to and management of randomization information will be carried out independently from the tasks of the clinical investigator or trial sponsor.

**Justification of sample size**
The hypothesis of this study is that the treatment success rate at 24 months of treatment for MDR-TB using the new regimen including new anti-TB drugs will not be inferior to that of conventional treatment regimens (non-inferiority test).

**Hypotheses for sample size calculation**
The sample size calculation hypotheses are defined as follows.

- **H₀ (null hypothesis):** \( P_T - P_C \leq \delta \) (new regimen treatment success rate after 24 months of treatment is inferior to conventional treatment success rate).
- **H₁ (alternative hypothesis):** \( P_T - P_C > \delta \) (new regimen treatment success rate at 24 months is not inferior to conventional treatment success rate).

**Assumptions**
Based on the results of our previous study, we presume the 24-month treatment success rate of the control arm as 80% [16, 17]. Based on an \( \alpha = 0.025 \) level of significance (one-sided test), a power of 80%, < 10% difference in treatment success rates between the control and investigational arms (80% vs. 70%) when we anticipate that the actual success rate in the treatment group will be 90%, the sample size per arm to show non-inferiority of the investigational regimen was calculated to be 48. Additionally, reflecting (1) proportion of fluoroquinolone-susceptible MDR-TB among participants as 50%, and (2) anticipating 5% loss to follow-up, the final number of participants is calculated...
as \( N/(0.50 \times 0.95) \), resulting in 102 persons/group (204 in total).

If a participant withdraws for any reason within 2 weeks after enrollment, that participant will be replaced. Considering the number of replaced participants, the enrollment accrual ceiling is 220 persons maximum.

### Statistical analysis

The results of this trial for efficacy outcomes will be analyzed based on both modified intention-to-treat (mITT) and per protocol (PP) approaches with a primary consideration for mITT results. A PP analysis will be performed secondarily. A safety analysis will be performed based on the safety group. The mITT group will include participants who are randomized after satisfying eligibility criteria and receive study drugs at least one time. The PP group will include participants who satisfy the following conditions among the mITT group: (1) those who completed > 80% of the planned treatment, (2) those who completed the clinical trial according to the protocol. The safety analysis group will include participants who receive study drugs at least once.

#### Efficacy outcomes

Comparisons will be performed using two-sided tests with a statistical significance level of 5% unless stated otherwise.

##### Analysis of primary outcome

For the primary outcome of this trial, we will describe the treatment success rate at 24 months of the control arm and the investigational arm with a two-sided 95% confidence interval. To test for non-inferiority of the investigational arm, when the lower limit of the one-sided 97.5% confidence interval of the difference \( (P_T - P_C) \) between investigational and control arms is larger than the non-inferiority margin of \(-10\%\), it will be concluded that the treatment success rate of the investigational arm shows non-inferiority to the treatment success rate of the control arm.

##### Analysis of secondary outcomes

The analysis of secondary outcomes will be described as exploratory outcomes. To determine whether time to sputum culture conversion after treatment start is statistically different between the control and investigational arms, the median time will be estimated in each group using the Kaplan-Meier method, and the difference in the distribution of time to culture conversion of the two arms will be compared using the log-rank test.

To test whether there is a statistical difference in proportion of sputum culture conversion (liquid and solid culture media) at 2 months or 6 months of treatment, treatment

### Table 1 Dose and schedule of anti-TB drugs recommended by the Korean national guidelines [37]

| Drug          | Dose                           | Usage             |
|---------------|--------------------------------|-------------------|
| Pyrazinamide  |                                |                   |
|               | 1000 mg (< 50 kg)              | 2000 mg           |
|               | 1500 mg (50–70 kg)             |                   |
|               | 2000 mg (> 70 kg)              |                   |
| Kanamycin     | 15 mg/kg (< 50 years)          | 1000 mg (< 50 years) | Once, intramuscularly |
| Amikacin      | 10 mg/kg (≥ 50 years)          | 750 mg (≥ 50 years) |                   |
| Streptomycin  |                                |                   |
| Capreomycin   |                                |                   |
| Cycloserine   | 500 mg (< 50 kg)               | 1000 mg           |
|               | 750 mg (50–70 kg)              |                   |
|               | 750–1000 mg (> 70 kg)          |                   |
| Prothionamide | 500 mg (< 50 kg)               | 1000 mg           |
|               | 750 mg (50–70 kg)              |                   |
|               | 750–1000 mg (> 70 kg)          |                   |
| p-aminosalicylic acid | 150 mg/kg | 12 g | Divide in two, after meal |
| Levofloxacin  | 750 mg (< 50 kg)               | 1000 mg           |
|               | 1000 mg (50–70 kg)             |                   |
| Moxifloxacin  | 400 mg                         | 400 mg            |

### Table 2 Dose and schedule of anti-TB drugs of investigational arm

| Drug          | Dose                           | Usage             |
|---------------|--------------------------------|-------------------|
| Linezolid     | 600 mg/day for initial 2 months, then 300 mg/day | Once |
| Delamanid     | 200 mg/day                      | Divide in two, together with meal |
| Levofloxacin  | 750 mg (< 50 kg)               | Once, before or after meal |
|               | 1000 mg (50–70 kg)             |                   |
| Pyrazinamide  | 1000 mg (< 50 kg)              | Once              |
|               | 1500 mg (50–70 kg)             |                   |
|               | 2000 mg (> 70 kg)              |                   |
success at the end of treatment, reverting to positive sputum culture after the end of treatment, treatment success according to pyrazinamide resistance, and death between the control and investigational arms, proportions of each arm will be summarized by frequency and percentage and these will be compared using the chi-square test and Fisher’s exact test. The median time to death after treatment start will be estimated in each group using Kaplan-Meier method, and the difference in the distribution of time to death of the two arms will be compared using the log-rank test.

**Safety assessment**

All AEs and serious AEs (SAEs) according to the Common Terminology Criteria for Adverse Events (CTCAE), regardless of severity, seriousness, or relationship to the study drug, will be collected and documented.

We will summarize all AEs and SAEs, AE frequency and percentage, and 95% confidence intervals. Additionally, we will summarize and evaluate the occurrence rate of AEs in relationship to the study drug and severity. The occurrence rate of ADEs (CTCAE grades 3 and 4) of the two arms and the proportion per type of toxicity will be compared using the chi-square test or Fisher’s exact test.

**Stratified analysis**

Primary and secondary outcomes will be analyzed separately in participants with sputum smear-positive and smear-negative pulmonary TB.

---

**Table 3** Study timeline for control arm

| Weeks (w) | Screening | Baseline visit* | Treatment | End of treatment* (End of study) |
|-----------|-----------|-----------------|-----------|----------------------------------|
| –2 w ~ –1 day | NA        | NA              | ± 4 days  | ± 2 w                             |
| Consent   | X         | X               | ± 4 days  | ± 2 w                             |
| Randomization | X          | X               | ± 4 days  | ± 2 w                             |
| Medical history | X          | X               | ± 4 days  | ± 2 w                             |
| Physical exam | X         | X               | ± 4 days  | ± 2 w                             |
| Neurological exam | X           | X               | ± 4 days  | ± 2 w                             |
| Sputum AFB smear | X ^o     | X ^o            | ± 4 days  | ± 2 w                             |
| TB culture (solid) | X ^o    | X ^o            | ± 4 days  | ± 2 w                             |
| TB culture (liquid) | X ^o   | X ^o            | ± 4 days  | ± 2 w                             |
| Genotypic DST | If available | With first/reverted cultured Mycobacterium tuberculosis | ± 4 days  | ± 2 w                             |
| Phenotypic DST ^b | With first/reverted cultured Mycobacterium tuberculosis | ± 4 days  | ± 2 w                             |
| CXR ^h | X ^o     | X ^o            | ± 4 days  | ± 2 w                             |
| Chemistry, electrolytes | X ^o    | X ^o            | ± 4 days  | ± 2 w                             |
| Complete blood count | X ^o    | X ^o            | ± 4 days  | ± 2 w                             |
| ECG | X ^e     | X ^e            | ± 4 days  | ± 2 w                             |
| Urine HCG ^c | X         | X               | ± 4 days  | ± 2 w                             |
| HIV, HBV ^d | X         | X ^o            | ± 4 days  | ± 2 w                             |
| Optic test | X         | X               | ± 4 days  | ± 2 w                             |

AFB acid-fast bacilli, CXR chest x-ray, DST drug susceptibility testing, ECG electrocardiogram, HBV hepatitis B virus, HCG human chorionic gonadotropin, HIV human immunodeficiency virus, NA not applicable, TB tuberculosis

*Administration of anti-TB regimen can begin at baseline visit since drug-resistant TB must be treated immediately

*Drug susceptibility test for isoniazid, rifampicin, ethambutol, pyrazinamide, streptomycin, kanamycin, amikacin, capreomycin, ofloxacin, levofloxacin, moxifloxacin, prothionamide, cycloserine, and p-aminosalicylic acid (can be omitted for patients with results already provided)

*Only in females of childbearing potential (blood HCG test results are available)

*Study drugs can be administered before obtaining the results since eligibility is not determined by these results

*Can be omitted if previous tests except ECG were done within 4 weeks. In case of ECG, within 1 week

*Check prohibited drugs for exclusion criteria at screening visit and check immunosuppressants including steroids after enrollment

*End of treatment visit will be determined by the time of culture conversion

*Can be omitted if previous test was done within 2 weeks
Table 4: Study timeline for investigational arm

| Weeks (w) | Screening | Baseline visita | Treatment | End of treatment (EOT)b | EOT to end of study |
|-----------|-----------|----------------|-----------|-------------------------|---------------------|
|           |           |                 |           | 40 w ~ 52 w             | ~ 24 months (every 2 months) |
| Visit window | NA  | NA | ±4 days | ±1w | ±2 w | ±2 w | ±2 w |
| Consent | X | | | | | |
| Randomization | | | | | | |
| Medical history | X | | | | | |
| Physical exam | X | X | X | X | X | X | X |
| Neurological exam | X | X | X | X | X | X | X |
| Sputum AFB smear | X | X | X | X | X | X | X |
| TB culture (solid) | X | X | X | X | X | X | X |
| TB culture (liquid) | X | X | X | X | X | X | X |
| Genotypic DST | X | X | X | X | X | X | X |
| Phenotypic DSTc | X | X | X | X | X | X | X |
| Resistance test | X | X | X | X | X | X | X |
| CXR | X | X | X | X | X | X | X |
| Chemistry, electrolytes | X | X | X | X | X | X | X |
| Complete blood count | X | X | X | X | X | X | X |
| ECG | X | X | X | X | X | X | X |
| Urine HCGd | X | X | X | X | X | X | X |
| HIV, HBVd | X | X | X | X | X | X | X |
| Optic test | X | X | X | X | X | X | X |
| Compliance of drug intake | X | X | X | X | X | X | X |
| Adverse drug reaction | X | X | X | X | X | X | X |
| Other medicatione | X | X | X | X | X | X | X |

AFB acid-fast bacilli, CXR chest x-ray, DST drug susceptibility testing, ECG electrocardiogram, HBV hepatitis B virus, HCG human chorionic gonadotropin, HIV human immunodeficiency virus, NA not applicable, TB tuberculosis

aData administration of anti-TB regimen can begin at baseline visit since drug-resistant TB must be treated immediately.

bDrug susceptibility test for isoniazid, rifampicin, ethambutol, pyrazinamide, streptomycin, kanamycin, amikacin, capreomycin, ofloxacin, levofloxacin, moxifloxacin, prothionamide, cycloserine, and p-aminosalicylic acid (can be omitted for patients with results already provided).

DStudy drugs can be administered before obtaining results since eligibility is not determined by these results.

End of study visit will be determined by the time of culture conversion. Omit test after end of treatment visit.

AData collection and management

This study will use a web-based electronic case report form (e-CRF) with Pharmaco-epidemiology and Clinical Trial Application X (PhactaX). PhactaX has been developed by the MRCC in collaboration with an outsourced contractor. PhactaX is based on Java and Oracle databases and complies with international standards and regulations. The e-CRF designed for this study used dummy variables for user acceptance testing to confirm its validity.

During the study, medical personnel not participating in this study will monitor this trial. Monitors will visit sites to monitor all aspects of the study including adherence to the protocol and Good Clinical Practice, protection of study participants, and data accuracy of the study.

Supervision of the trial

A Data and Safety Monitoring Board (DSMB) composed of two respiratory specialists who have experience with treating MDR-TB patients and one statistician from another institute with no conflict of interests will be formed. The DSMB will review data every 3 months during the trial and may provide recommendations such as change, continuation, or stopping of protocols to the investigators based on the results.

Confidentiality

Collection and operation of participants’ personal information will be limited to only information necessary for efficacy, safety, and tolerability evaluation of study drugs.
Treatment success The sum of Cured and Treatment completed

Not evaluated A patient for whom no treatment outcome is known

Lost to follow-up A patient whose treatment was interrupted for reasons: a) 2 consecutive months or more b) regimen change of at least two anti-TB drugs c) evidence of additional acquired resistance to fluoroquinolones or second-line injectable drugs d) adverse drug reactions e) national policy without evidence of failure BUT no record of culture conversion after the intensive phase

Died A patient who dies for any reason during the course of treatment

Treatment failed Treatment terminated or need for permanent regimen change of at least two anti-TB drugs because of: a) lack of conversion by the end of the intensive phase; or b) bacteriological reversion in the continuation phase after conversion to negative; or c) evidence of additional acquired resistance to fluoroquinolones or second-line injectable drugs; or d) adverse drug reactions

Such data will be collected and processed taking precautions for compliance with laws on privacy protection and guaranteeing of confidentiality. Paper files containing participants’ data (including personally identifiable information and copies of signed consent forms) will be securely stored in a locked office on sites in locked filing cabinets. Digital files containing participants’ data will be stored in password-protected files on university-maintained servers. Access to study files will be restricted to authorized personnel only.

The items in the present study protocol comply with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist (see Additional file 1).

Discussion

Several trials have been conducted with the aim of overcoming difficulties in MDR-TB treatment. In 2010, a relapse-free cure rate of 87.9% among 206 patients treated with a 9-month regimen of rifampicin, clofazimine, ethionamide, and pyrazinamide throughout the treatment period supplemented with prothionamide, kanamycin, and high-dose isoniazid during an intensive phase of 4 months was reported [18]. This result was largely replicated in subsequent studies [19], and WHO endorsed a shorter course regimen in 2016 [5].

However, this shorter regimen includes too many drugs, as many as seven, and still includes an injectable (kanamycin) for the first 4–6 months. Additionally, the number of candidates for this shorter treatment, i.e., patients without resistance to all drugs included in the regimen, could be limited. In European MDR-TB cohorts, on average, only 7.8% were eligible for this shortened regimen [20]. Reports from other areas, including Singapore, Brazil, Pakistan, and South Korea, assume eligibility for the shorter regimen ranged from 30 to 55% [21–24].

Fortunately, repurposed anti-TB drugs including linezolid or newly developed drugs including delamanid and bedaquiline have been introduced for MDR-TB treatment. A meta-analysis of 12 non-randomized studies showed that 82% of patients treated with a linezolid-containing regimen demonstrated favorable treatment outcomes [8]. Additionally, a randomized trial in which linezolid was used for XDR-TB patients reported a 6-month culture conversion rate of 87% and a treatment success rate without relapse at 1 year follow-up of 71% [9, 25]. Delamanid, a nitro-dihydro-imidazooxazole derivative, demonstrated activity against MDR-TB as measured by increased sputum culture conversion rate in a randomized, placebo-controlled trial. Patients who received a background drug regimen plus 100 mg or 200 mg of delamanid twice daily had sputum culture conversion rates in liquid broth at 2 months of 45.4% and 41.9%, respectively, as compared with 29.6% of patients who received a background drug regimen plus placebo [10]. In a subsequent observational extension trial for 24 months, favorable outcomes were observed in 74.5% of patients who received delamanid for ≥6 months compared with 55% of patients who received delamanid for ≤2 months [26]. Bedaquiline, a diaryquino-line, showed efficacy in a randomized phase II trial; it increased the culture conversion rate to 62% and the cure rate to 58% at 120 weeks as compared with the placebo group (44% and 32%, respectively) [27]. Additionally, bedaquiline-containing regimens achieved high conversion and treatment success rates in a different large retrospective observational study [28].

Based on the proven efficacy of these new anti-TB drugs, several clinical trials using 6–12-month regimens for MDR-TB treatment without an injectable are being tested. First, the STREAM Stage 2 trial (NCT02409290, phase III) is comparing the effectiveness of 6- and 9-month bedaquiline-containing regimens against the conventional WHO regimen and a 9-months regimen including an injectable. Another phase III trial (NeXT, NCT02454205) is testing 6- or 9-month treatments containing bedaquiline, linezolid, levofloxacin, ethionamide/high-dose isoniazid, and pyrazinamide.
Additionally, NiX-TB (NCT02333799, phase III) is assessing the safety and efficacy of a 6- or 9-month regimen comprising bedaquiline, PA-824, and linezolid.

The present study, Treatment Shortening of MDR-TB Using Existing and New Drugs (MDR-END), tests a 9–12-month regimen of delamanid, linezolid, levofloxacin, and pyrazinamide for MDR-TB patients without fluoroquinolone resistance. Delamanid and linezolid were selected based on their bactericidal activities in a mouse model [29, 30] and proven effectiveness in MDR-TB patients [10, 17, 26, 31, 32], as well as on limited prior population exposure. In addition, levofloxacin was selected based on bactericidal activity [33], and it demonstrated effectiveness in MDR-TB patients [34] and weaker QT prolongation potential than moxifloxacin [35]. Finally, pyrazinamide was included because of its bactericidal sterilizing activity [15, 36] as well as its confirmed effectiveness in patients with MDR-TB [34].

Showing non-inferiority, although not superiority, of a shorter regimen without an injectable to the conventional regimen for MDR-TB treatment lasting 20–24 months is very important. Poor adherence to treatment is one of the main causes of poor treatment outcome among patients with MDR-TB, and it is strongly influenced by the long treatment duration and use of an injectable, which can cause ototoxicity or nephrotoxicity as well as pain at the injection site. If our trial proves non-inferiority of the 9–12-month fully oral regimen to the conventional 2-year treatment including an injectable, then this shorter regimen could contribute to reducing MDR-TB globally by improving patient adherence to treatment.

**Trial status**

Recruitment began at the first site in April 2016 and is expected to be completed by April 2021.

**Additional file**

[Additional file 1: SPIRIT 2013 checklist: recommended items to address in a clinical trial protocol and related documents. (DOC 127 kb)](#)

**Abbreviations**

ADE: Adverse drug event; AE: Adverse event; AFB: Acid-fast bacilli; CTCAE: Common Terminology Criteria for Adverse Events; DSMB: Data and Safety Monitoring Board; DST: Drug susceptibility testing; e-CRF: Electronic case report form; ITT: Intention-to-treat; MTB: Mycobacterium tuberculosis; MDR: Multidrug-resistant; MRCC: Medical Research Collaborating Center; PAS: p-aminosalicylic acid; PhactaX: Pharmaco-epidemiology and Clinical Trial Application X; PP: Per protocol; RR: Rifampicin-resistant; SAE: Serious adverse event; TB: Tuberculosis; XDR: Extensively drug-resistant

**Funding**

This study was supported by a grant from the Korea Centers for Disease Control and Prevention, Republic of Korea (#2015-177). Linezolid (Zyvox®) was donated by Pfizer Inc. (New York, NY, USA). Delamanid (Deltibra®) was donated by Korea Otsuka Pharmaceutical Co. Ltd. The funders and donors had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Availability of data and materials**

The results of this trial will be disseminated only by presentation at academic meetings or publication in academic journals.

**Authors’ contributions**

The authors meet all four criteria of the International Committee of Medical Journal Editors. JJJY conceived the study and participated in its design. ML, TSS, WK, JI, and YAK also contributed to the study design. JJJY and ML drafted the manuscript. SH was in charge of statistical considerations in the study design. HA, HWJ, and JJJY constructed a database for this study. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

The trial received ethical approval from the Institutional Review Boards of all participating sites: Seoul National University Hospital (approval number H-1508-105-696), National Medical Center (approval number H-1602-063-002), Dankook University Hospital (approval number DKUH 2016-03-001), Pusan National University Hospital (approval number H-1602-010-053), Korea University Ansan Hospital (approval number AS16181), Samsung Medical Center (approval number SMC 2016-02-122), Asan Medical Center (approval number 2016-0316), Seoul Metropolitan Government (SMG)-Seoul National University (SNU) Boramae Medical Center (approval number 26-2016-22), Pusan National University Yangsan Hospital (approval number 04-2016-003), Severance Hospital, Yonsei University College of Medicine (approval number 4-2016-0141). Ullean University Hospital (approval number UUH 2016-02-013), and the Catholic University of Korea Incheon St. Mary's Hospital (approval number OC16MNM50020). Participants must provide signed and dated written informed consent prior to undergoing any study-specific procedures.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1Clinical Research Section, International Tuberculosis Research Center, 247, Jangchungdan-ro, Jung-gu, Seoul 04564, Republic of Korea. 2Division of Pulmonology, Allergy and Critical Care Medicine, Department of Internal Medicine, Pusan National University Hospital, 179, Gudeok-ro, Seo-gu, Busan 49241, Republic of Korea. 3Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Boramae Medical Center, 20, Boramae-ro 5-gil, Dongjak-gu, Seoul 07061, Republic of Korea. 4Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea. 5Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Iwhoon-ro, Gangnam-gu, Seoul 06351, Republic of Korea. 6Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Pusan National University Yangsan Hospital, 20, Geumo-ro, Mulgeum-eup, Yangsan-si, Gyeongsangnam-do 50612, Republic of Korea. 7Division of Pulmonary, Ulsan University Hospital, University of Ulsan College of Medicine, 877, Bangeojinunhwando-ro, Dong-gu, Ulsan 44033, Republic of Korea. 8Department of Pulmonology, Korea University Ansan Hospital, 123, Jeoljeum-ro, Danwon-gu, Ansan, Gyeonggi-do 15355, Republic of Korea. 9Ulsan University Hospital, Department of Pulmonology and Critical Care Medicine, Department of Internal Medicine, The Catholic University of Korea, Incheon St. Mary’s Hospital, 56, Dongusu-ro, Bupyeong-gu, Incheon 21431, Republic of Korea. 10Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Dankook University Hospital, 201, Mangyang-ro, Dongnam-gu, Cheorwon-si, Chungcheongnam-do 31116, Republic of Korea. 11Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, National Medical Center, 245, Eulji-ro, Jung-gu, Seoul 04564, Republic of Korea. 12Division of Pulmonology, Department of Internal Medicine, Institute of Chest Diseases, Severance Hospital, Yonsei University College of Medicine, 50-1, Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea. 13Division of Pulmonary and Critical Care Medicine, Department of...
Internal Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 13620, Republic of Korea. 14Seoul Clinical Laboratories, 13, Heungdeok 1-ro, Heung-gu, Yongin, Gyeonggi-do 16954, Republic of Korea. 15Laboratory Medicine Center, The Korean Institute of Tuberculosis, 168-5, Osongsaengmyeong 4-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do 28158, Republic of Korea. 16Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 7701, Cape Town, South Africa. 17Department of Microbiology, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, 50-1, Younse-ro, Seodaemun-gu, Seoul 03722, Republic of Korea. 18Medical Research Collaborating Center, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea. 19Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, 103, Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea.

Received: 6 March 2018 Accepted: 14 November 2018

Published online: 16 January 2019

References
1. World Health Organization. Global tuberculosis report 2014. 2014
2. World Health Organization. Global tuberculosis report 2017
3. Korea Centers for Disease Control and Prevention. Annual report on the notification of tuberculosis in Korea 2016. Cheongju: Korea Centers for Disease Control and Prevention; 2016. p. 44.
4. Jeon D. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update: applicability in South Korea. Tuberc Respir Dis. 2017;80(4):336–43. https://doi.org/10.5111/trd.2017.80.4.336.
5. World Health Organization. Treatment guidelines for drug-resistant tuberculosis. 2016
6. Wu S, Zhang Y, Sun F, Chen M, Zhou L, Wang N, Zhan S. adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis. Am J Thorac. 2016;232(2):152–30. https://doi.org/10.1097/01.mgt.0000433951.09030.5a.
7. Carroll MW, Lee M, Cai Y, et al. Frequency of adverse reactions to first- and second-line anti-tuberculosis chemotherapy in a Korean cohort. Int J Tuberc Lung Dis. 2012;16:961–6.
8. Sotgiu G, Cenitis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR- and XDR-TB: systematic review and meta-analysis. Eur Respir J. 2012;41:1430–42. https://doi.org/10.1183/09031936.00229112.
9. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367;1508–18. https://doi.org/10.1056/NEJMoa1201964.
10. Gil M, Sotgiu V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366:2151–60. https://doi.org/10.1056/NEJMoa1112433.
11. Diacon AH, Pym A, Grobush M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360(23):2397–405. https://doi.org/10.1056/NEJMoa0908427.
12. Chang KC, Yew WW, Sotgiu G. Clinical research in the treatment of tuberculosis: current status and future prospects. Int J Tuberc Lung Dis. 2015;19(12):1417–27. https://doi.org/10.5588/tldt.15.0216.Review.
13. Joint Committee for the Revision of Korean Guidelines for Tuberculosis. Korean guidelines for tuberculosis. In: 2nd ed; 2014. http://www.lungkorea.org/thesis/file/korean_guidelines_for_tuberculosis_2014.pdf.
14. Jeon D. Medical management of drug-resistant tuberculosis. Tuberc Respir Dis (Seoul). 2015;78(3):168–74. https://doi.org/10.4046/2015.78.3.168.Epub 2015 Jun 30.
15. World Health Organization. Companion handbook to the guidelines for the programmatic management of drug-resistant tuberculosis, vol. 2014. http://apps.who.int/iris/bitstream/10665/139018/1/9789241548097_eng.pdf.
16. Kwak N, Kim HR, Yoo CG, Kim YW, Han SK, Yim JJ. Changes in treatment outcomes of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2015;19(5):525–30. https://doi.org/10.5588/tldt.14.0739.
17. Kang Y, Shim TS, Kim H, et al. Choice between levofloxacin and moxifloxacin and multidrug-resistant tuberculosis treatment outcomes. Ann Am Thorac Soc. 2016;13(3):364–70. https://doi.org/10.1513/AnnalsATS.201510.6908C.
18. Van Deun A, Maug AK, Salim MAH, Das PK, Sarker MR, Dana P, Rieder HL. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182:884–92.